Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | July 09, 2026 | July 13, 2026 |
| Denali Therapeutics Inc.DNLI · Entity 1735 | Director | June 03, 2026 | June 05, 2026 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date July 09, 2026 · Filed July 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,383 |
Ending reported balance
After 2026-07-09 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-07-09 · Exercise / conversion · Acquired 19,000 · Balance 27,383 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 2 · 2026-07-09 · Exercise / conversion · Acquired 112,422 · Balance 139,805 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 3 · 2026-07-09 · Exercise / conversion · Acquired 17,167 · Balance 156,972 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 4 · 2026-07-09 · Sale · Disposed 36,167 · Balance 120,805 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Row 5 · 2026-07-09 · Sale · Disposed 112,422 · Balance 8,383 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.45 · Expires 2032-06-22 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-09 · Exercise / conversion · Disposed 19,000 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F2: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2030-06-01 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-09 · Exercise / conversion · Disposed 112,422 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F3: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.75 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-07-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-07-09 · Exercise / conversion · Disposed 17,167 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F4: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026.
F2: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.
F3: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
F4: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Denali Therapeutics Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 32,483 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 6,408 · Balance 32,483 F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2: Includes 6,408 unvested RSUs. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.66 · Expires 2036-06-03 | Direct | 19,226 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 19,226 · Balance 19,226 F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
F2: Includes 6,408 unvested RSUs.
F3: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.
Jazz Pharmaceuticals plc
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,736 |
Ending reported balance
After 2026-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-31 · Tax withholding · Disposed 14 · Balance 12,428 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Row 2 · 2026-08-31 · Tax withholding · Disposed 1,692 · Balance 10,736 F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 21:20 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,692 | $241.39 | $408,431.88 |
DisclosureSEC source: 0001754371-26-000007 · edgardoc.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,736 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 31, 2026 Filed Sep 2, 2026 21:20 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 14 | $244.06 | $3,416.90 |
DisclosureSEC source: 0001754371-26-000007 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,428 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 05, 2026 Filed Aug 7, 2026 21:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 1,605 | $0.00 | $0.00 |
DisclosureSEC source: 0001754371-26-000004 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,442 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 23, 2027. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,167 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · derivative · entry 8 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,167 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F4 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 112,422 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · derivative · entry 7 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,422 shares Expires 2030-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F3 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · derivative · entry 6 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,000 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F2 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 112,422 | $90.00 | $10,117,980.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · nonDerivative · entry 5 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,383 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 36,167 | $84.00 | $3,038,028.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · nonDerivative · entry 4 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,805 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 17,167 | $16.75 | $287,547.25 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · nonDerivative · entry 3 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 156,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 112,422 | $29.00 | $3,260,238.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,805 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 20:40 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 19,000 | $8.45 | $160,550.00 |
DisclosureSEC source: 0001470831-26-000708 · wk-form4_1783975232.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 24, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,167 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · derivative · entry 8 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,167 Underlying: Common Stock · 17,167 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F6 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 24, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · derivative · entry 7 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F5 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 24, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 37,167 | $70.00 | $2,601,690.00 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · nonDerivative · entry 5 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,383 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 24, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 17,167 | $16.75 | $287,547.25 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · nonDerivative · entry 4 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 24, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 20,000 | $8.45 | $169,000.00 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · nonDerivative · entry 3 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,383 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,196 | $68.57 | $150,579.72 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,383 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 5,277 | $0.00 Strike: $68.92 | $0.00 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · derivative · entry 6 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,277 Underlying: Common Stock · 5,277 shares Expires 2036-06-21 F4 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 22:06 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 3,990 | $0.00 | $0.00 |
DisclosureSEC source: 0001470831-26-000636 · wk-form4_1782338786.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,579 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,167 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · derivative · entry 6 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,334 Underlying: Common Stock · 17,167 shares Expires 2033-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F5 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionStock Option (Right to Buy) · Derivative | 65,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · derivative · entry 5 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 65,921 shares Expires 2032-06-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F4 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 1,503 | $67.14 | $100,915.18 |
DisclosureSEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 4 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,589 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F3 · price: Represents the weighted average sale price of the shares sold from $67.10 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 88,737 | $66.62 | $5,911,241.88 |
DisclosureSEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 3 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,092 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. F2 · price: Represents the weighted average sale price of the shares sold from $66.10 to $67.095 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 17,167 | $16.75 | $287,547.25 |
DisclosureSEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:45 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 65,921 | $8.45 | $557,032.45 |
DisclosureSEC source: 0001470831-26-000550 · wk-form4_1781729104.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,662 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 16, 2026. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 19,226 | $0.00 Strike: $19.66 | $0.00 |
DisclosureSEC source: 0001754371-26-000002 · wk-form4_1780692201.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,226 Underlying: Common Stock · 19,226 shares Expires 2036-06-03 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:43 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001754371-26-000002 · wk-form4_1780692201.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,483 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,408 unvested RSUs. Read SEC document |
| August 08, 2025 Filed Aug 11, 2025 21:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,805 | $111.25 | $200,805.17 |
DisclosureSEC source: 0001765581-25-000094 · edgardoc.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,837 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 21:47 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,507 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000094 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,642 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 8,425 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0000950170-25-089670 · ownership.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,425 Underlying: Common Stock · 8,425 shares Expires 2035-06-19 F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 23:10 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantCommon Stock | 6,589 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089670 · ownership.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,741 F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors. F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 18,111 | $0.00 Strike: $13.93 | $0.00 |
DisclosureSEC source: 0001714899-25-000142 · wk-form4_1749155629.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,111 Underlying: Common Stock · 18,111 shares Expires 2035-06-03 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 20:34 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 6,037 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-25-000142 · wk-form4_1749155629.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,075 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 6,037 unvested RSUs. Read SEC document |
| August 06, 2024 Filed Aug 6, 2024 22:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,484 | $111.35 | $165,243.40 |
DisclosureSEC source: 0001765581-24-000073 · edgardoc.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,135 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 22:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000073 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,619 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 25, 2025. Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (Right to Buy) · Derivative | 26,014 | $0.00 Strike: $27.36 | $0.00 |
DisclosureSEC source: 0000950170-24-077440 · ownership.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,014 Underlying: Common Stock · 26,014 shares Expires 2034-06-20 F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer. Read SEC document |
| June 06, 2024 Filed Jun 11, 2024 00:06 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | SaleCommon Stock | 1,458 | $21.73 | $31,682.34 |
DisclosureSEC source: 0001714899-24-000145 · wk-form4_1718064363.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,038 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted March 7, 2024. F2 · balance_after: Includes 5,967 unvested RSUs. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,901 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001714899-24-000137 · wk-form4_1717540199.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,901 Underlying: Common Stock · 17,901 shares Expires 2034-05-31 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 22:30 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 5,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-24-000137 · wk-form4_1717540199.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,496 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 5,967 unvested RSUs. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 21:31 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 417 | $119.27 | $49,735.59 |
DisclosureSEC source: 0001765581-23-000108 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,888 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 21:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,241 | $138.16 | $171,454.20 |
DisclosureSEC source: 0001765581-23-000076 · edgardoc.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,305 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $137.69 to $138.16. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 21:44 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000076 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,546 F1 · kind: Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2024. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:15 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 51,501 | $0.00 Strike: $16.75 | $0.00 |
DisclosureSEC source: 0001209191-23-039347 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,501 Underlying: Common Stock · 51,501 shares Expires 2033-06-21 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 12,649 | $0.00 Strike: $30.92 | $0.00 |
DisclosureSEC source: 0001714899-23-000097 · wk-form4_1686002689.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,649 Underlying: Common Stock · 12,649 shares Expires 2033-06-01 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:04 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantCommon Stock | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001714899-23-000097 · wk-form4_1686002689.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,529 F1 · shares: Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 100% of the RSUs shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. F2 · balance_after: Includes 4,216 unvested RSUs. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 00:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 420 | $154.68 | $64,965.56 |
DisclosureSEC source: 0001765581-22-000132 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,471 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 08, 2022 Filed Aug 9, 2022 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,089 | $152.32 | $165,879.42 |
DisclosureSEC source: 0001765581-22-000082 · edgardoc.xml · nonDerivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,891 F2 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 22:09 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-22-000082 · edgardoc.xml · nonDerivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,980 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 28, 2023. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:25 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039232 · doc4.xml · derivative · entry 1 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 02, 2022 Filed Jun 7, 2022 00:08 UTC | Denali Therapeutics Inc. DNLI · Entity 1735 | GrantStock Option (right to buy) · Derivative | 17,959 | $0.00 Strike: $24.27 | $0.00 |
DisclosureSEC source: 0001714899-22-000093 · wf-form4_165456048293686.xml · derivative · entry 2 Cook Jennifer E. · CIK 0001754371 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,959 Underlying: Common Stock · 17,959 shares Expires 2032-06-02 F3 · derivative.exercise_date: 100% of the shares subject to the option shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.